Source comparison
Tesamorelin vs Egrifta: Full Comparison
Before selecting a tesamorelin formulation for research purposes, understanding the regulatory, practical, and cost distinctions between branded Egrifta and research-grade tesamorelin helps clarify which option aligns with study requirements and compliance fra
This comparison does not assign a generated winner or score.
- Before selecting a tesamorelin formulation for research purposes, understanding the regulatory, practical, and cost distinctions between branded Egrifta and research-grade tesamorelin helps clarify which option aligns with study requirements and compliance frameworks.
- Active Compound
- Tesamorelin acetate (44-amino-acid GHRH analogue)
- Tesamorelin acetate (identical sequence)
- No chemical difference. Same molecule
- FDA Approval Status
- FDA-approved for HIV-associated lipodystrophy (2010)
- Not FDA-approved as a drug product
- Egrifta carries a therapeutic indication; research-grade does not
- Manufacturing Oversight
- cGMP under FDA inspection and batch verification
- cGMP without FDA batch-level oversight
- Both follow cGMP, but Egrifta has regulatory enforcement
- Purity Standards
- >98% (verified per FDA submission standards)
- >98% (verified by third-party HPLC and mass spec)
- Equivalent purity when sourced from reputable suppliers
- Formulation
- 2mg lyophilised powder in single-use vials
- Variable. Typically 2–5mg per vial, lyophilised
- Egrifta uses standardised excipients; research-grade varies
- Typical Cost
- $3,000–$4,500/month (30-day supply at 2mg/day)
- $150–$300/month (same dosing protocol)
- Research-grade is 90–95% less expensive
- Primary Use Case
- Clinical prescription for approved indication
- Laboratory research, investigational studies
- Egrifta for clinical settings; research-grade for non-clinical use